骨髓瘤自体干细胞移植的未来。
The future of autologous stem cell transplantation in myeloma.
作者信息
van Rhee Frits, Giralt Sergio, Barlogie Bart
机构信息
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and.
Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
出版信息
Blood. 2014 Jul 17;124(3):328-33. doi: 10.1182/blood-2014-03-561985. Epub 2014 Jun 3.
Abstract
Autologous stem cell transplantation (ASCT) has long been considered frontline therapy for newly diagnosed myeloma patients. This Spotlight examines the role of ASCT in the era of novel drugs and argues that ASCT should continue to be considered for eligible patients. A combination of novel drugs with ASCT in a sequential treatment approach can attain long-term survival and perhaps cure a subset of patients. ASCT will likely remain an important platform to develop curative strategies in the foreseeable future.
摘要
自体干细胞移植（ASCT）长期以来一直被视为新诊断骨髓瘤患者的一线治疗方法。本专题探讨了ASCT在新药时代的作用，并认为对于符合条件的患者仍应继续考虑采用ASCT。将新药与ASCT按序贯治疗方法联合使用可实现长期生存，甚至可能治愈一部分患者。在可预见的未来，ASCT可能仍将是制定治愈策略的重要平台。
相似文献
1
The future of autologous stem cell transplantation in myeloma.骨髓瘤自体干细胞移植的未来。
Blood. 2014 Jul 17;124(3):328-33. doi: 10.1182/blood-2014-03-561985. Epub 2014 Jun 3.
2
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.增强自体干细胞移植以改善骨髓瘤的治疗效果。
Biol Blood Marrow Transplant. 2016 Nov;22(11):1926-1937. doi: 10.1016/j.bbmt.2016.06.004. Epub 2016 Jun 8.
3
Evolving role of stem cell transplantation in multiple myeloma.干细胞移植在多发性骨髓瘤中不断演变的作用。
Clin Lymphoma Myeloma. 2005 Sep;6(2):89-95. doi: 10.3816/CLM.2005.n.034.
4
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.新型药物时代老年初诊多发性骨髓瘤患者的自体干细胞移植。
Ann Oncol. 2014 Jan;25(1):189-95. doi: 10.1093/annonc/mdt509.
5
Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.自体干细胞移植在第一次缓解期与多发性骨髓瘤患者更好的无进展生存期相关。
Ann Hematol. 2018 Oct;97(10):1869-1877. doi: 10.1007/s00277-018-3370-1. Epub 2018 May 21.
6
[Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].硼替佐米诱导治疗后自体造血干细胞移植治疗多发性骨髓瘤
Zhonghua Nei Ke Za Zhi. 2014 Nov;53(11):865-72.
7
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.自体干细胞移植联合来那度胺维持治疗强化可改善新诊断完全缓解的多发性骨髓瘤患者的生存结局。
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.
8
The role of transplant in multiple myeloma.移植在多发性骨髓瘤中的作用。
J Natl Compr Canc Netw. 2014 Aug;12(8):1131-8. doi: 10.6004/jnccn.2014.0110.
9
Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.对于接受初次单次自体移植的多发性骨髓瘤患者，自体干细胞移植前的完全缓解状态是一个重要的预后因素。
Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.
10
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.适合自体移植的初诊多发性骨髓瘤患者维持治疗策略的进展。
Expert Rev Hematol. 2020 Dec;13(12):1333-1347. doi: 10.1080/17474086.2020.1839886. Epub 2020 Oct 26.
引用本文的文献
1
Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment.微小残留病检测：对临床诊断和癌症患者治疗的意义
MedComm (2020). 2025 May 15;6(6):e70193. doi: 10.1002/mco2.70193. eCollection 2025 Jun.
2
Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity.度维利塞是一种新型的NFAT抑制剂，可减轻阿达木单抗诱导的免疫原性。
Front Pharmacol. 2025 Jan 9;15:1397995. doi: 10.3389/fphar.2024.1397995. eCollection 2024.
3
Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.新型疗法时代多发性骨髓瘤患者外周血造血干细胞动员的预测因素：单中心经验。
Cancer Med. 2024 Jun;13(11):e7356. doi: 10.1002/cam4.7356.
4
An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.多发性骨髓瘤概述：一种单克隆浆细胞恶性肿瘤的诊断、管理及治疗方式
Saudi J Biol Sci. 2024 Feb;31(2):103920. doi: 10.1016/j.sjbs.2023.103920. Epub 2023 Dec 30.
5
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?多发性骨髓瘤中的异常DNA甲基化：主要障碍还是机遇？
Front Oncol. 2022 Aug 18;12:979569. doi: 10.3389/fonc.2022.979569. eCollection 2022.
6
Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model.使用临床基因组模型对多发性骨髓瘤进行预后分层：IAC-50模型的验证与性能分析
Hemasphere. 2022 Aug 2;6(8):e760. doi: 10.1097/HS9.0000000000000760. eCollection 2022 Aug.
7
Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT.接受自体造血干细胞移植（ASCT）的多发性骨髓瘤患者达到微小残留病（MRD）阴性状态时的分期的预后意义
Front Oncol. 2022 May 18;12:776920. doi: 10.3389/fonc.2022.776920. eCollection 2022.
8
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data.基于临床和基因表达数据的机器学习模型在多发性骨髓瘤患者中的生存预测和治疗优化。
Leukemia. 2021 Oct;35(10):2924-2935. doi: 10.1038/s41375-021-01286-2. Epub 2021 May 18.
9
Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.棉酚通过JUN-JNK途径诱导多发性骨髓瘤细胞凋亡。
Am J Cancer Res. 2020 Mar 1;10(3):870-883. eCollection 2020.
10
Autologous hematopoietic stem-cell transplant in small-sized and peripheral centers: a 10-year experiment.小型及周边中心的自体造血干细胞移植：一项为期10年的试验。
Ther Adv Hematol. 2019 Oct 5;10:2040620719879587. doi: 10.1177/2040620719879587. eCollection 2019.
本文引用的文献
1
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.在ECOG-ACRIN E4A03随机临床试验中，新诊断的多发性骨髓瘤患者接受来那度胺联合地塞米松治疗后早期进行自体干细胞移植的结果：长期随访
Blood Cancer J. 2016 Sep 2;6(9):e466. doi: 10.1038/bcj.2016.68.
2
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.单细胞遗传分析揭示了骨髓瘤起始克隆的组成以及分支和平行进化的系统发育模式。
Leukemia. 2014 Aug;28(8):1705-15. doi: 10.1038/leu.2014.13. Epub 2014 Jan 13.
3
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.多参数流式细胞术检测多发性骨髓瘤微小残留病：对 MRC 骨髓瘤 IX 研究结果的影响。
J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3.
4
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.硼替佐米巩固治疗多发性骨髓瘤自体干细胞移植后：北欧骨髓瘤研究组随机 3 期试验。
Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24.
5
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.自体/减低强度异基因干细胞移植与多发性骨髓瘤的自体移植：EBMT-NMAM2000 研究的长期结果。
Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.
6
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.总治疗 3 方案治疗多发性骨髓瘤中连续 18-氟-脱氧葡萄糖发射断层扫描的预后意义。
Blood. 2013 Mar 7;121(10):1819-23. doi: 10.1182/blood-2012-08-451690. Epub 2013 Jan 10.
7
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.沙利度胺和泼尼松作为 ASCT 后 MM 患者维持治疗的随机 3 期试验：加拿大国家癌症研究所临床试验组骨髓瘤 10 试验，具有生活质量评估。
Blood. 2013 Feb 28;121(9):1517-23. doi: 10.1182/blood-2012-09-451872. Epub 2013 Jan 7.
8
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.硼替佐米诱导和维持治疗新诊断多发性骨髓瘤患者：随机 III 期 HOVON-65/GMMG-HD4 试验结果。
J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16.
9
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.硼替佐米、沙利度胺和地塞米松（VTD）作为多发性骨髓瘤移植前诱导治疗的优势：一项随机 3 期 PETHEMA/GEM 研究。
Blood. 2012 Aug 23;120(8):1589-96. doi: 10.1182/blood-2012-02-408922. Epub 2012 Jul 12.
10
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?多发性骨髓瘤的连续 Total Therapy 试验改善了长期结果：患者现在是否被治愈了？
Leukemia. 2013 Jan;27(1):226-32. doi: 10.1038/leu.2012.160. Epub 2012 Jun 18.
Zotero 插件